Rebel Medicine
Rebel Medicine is a science-led pharmaceutical company focused on developing and commercializing innovative medicines using novel drug delivery technologies to better treat acute pain. Their mission is to promote health by delivering innovative and accessible medicines, aiming to create an opioid-free future and revolutionize acute pain management. They develop disruptive, non-opioid solutions for acute pain, leveraging proprietary drug delivery technologies to address unmet medical needs in pain management. The company emphasizes cost-effective design, rapid translation of therapies, and creating shared value. Rebel Medicine's pipeline includes products like Alevatrix™, RBL-001, Alevaderm™, and ALEVADERM, targeting postoperative pain, dental pain, dermal injuries, and wound care. They collaborate through strategic partnerships, licensing, and R&D collaborations, and are supported by a team of biomedical engineers, physicians, and entrepreneurs.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Injectable extended-release local anesthetic gel (multi-day analgesia)
An investigational injectable gel formulation of a local anesthetic designed for regional nerve block or local instillation to provide multi-day postoperative analgesia via a ready-to-use prefilled syringe.
Extended-release local anesthetic solution (36–48 h)
An extended-release solution formulation intended for rapid onset and 36–48 hours of analgesia after a single administration for surgical, dental, obstetrical, or diagnostic procedures.
Biodegradable drug-eluting wound dressing (up to 7 days)
A composite wound dressing designed to deliver topical local anesthetic over multiple days while promoting moist wound healing and reducing dressing changes.
Injectable extended-release local anesthetic gel (multi-day analgesia)
An investigational injectable gel formulation of a local anesthetic designed for regional nerve block or local instillation to provide multi-day postoperative analgesia via a ready-to-use prefilled syringe.
Extended-release local anesthetic solution (36–48 h)
An extended-release solution formulation intended for rapid onset and 36–48 hours of analgesia after a single administration for surgical, dental, obstetrical, or diagnostic procedures.
Biodegradable drug-eluting wound dressing (up to 7 days)
A composite wound dressing designed to deliver topical local anesthetic over multiple days while promoting moist wound healing and reducing dressing changes.
Services
Commercial and R&D partnership engagement including in-licensing, out-licensing, R&D collaborations, academic/military partnerships, and acquisition discussions.
Commercial and R&D partnership engagement including in-licensing, out-licensing, R&D collaborations, academic/military partnerships, and acquisition discussions.
Expertise Areas
- Acute and postoperative pain therapeutics
- Loco-regional anesthesia development
- Controlled-release drug delivery
- Wound care with sustained topical analgesia
Key Technologies
- Injectable sustained-release gel formulations
- Extended-release local anesthetic solutions
- Composite biodegradable drug-eluting wound dressings
- Prefilled syringe drug-device packaging